SEC filings and other documents

Envudeucitinib shows top efficacy in psoriasis; lupus strategy shifts to IFN-positive focus.

Envudeucitinib advances in psoriasis and targeted lupus populations, with new CNS and pipeline programs progressing.

Envudeucitinib showed strong efficacy in IFNGS-high SLE patients, guiding future phase III focus.

Envudeucitinib sets new efficacy benchmark in psoriasis; NDA and pivotal SLE data expected in 2026.

Envudeucitinib and A-005 deliver leading efficacy in immune diseases, targeting $180B+ markets.

Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise potential.

Envudeucitinib's strong Phase 3 results drive NDA plans as cash reserves support operations into 2027.

Envudeucitinib achieved high rates of complete skin clearance and rapid itch relief in phase III psoriasis trials.

Envudeucitinib achieved top Phase 3 results in psoriasis, driving a high-value, multi-indication pipeline.

Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise expansion ahead.

Strong Phase 3 psoriasis data and NDA planned; SLE pivotal trial readout expected in Q3.

Strong phase III psoriasis results and robust pipeline expansion, with NDA filing expected this year.

Envudeucitinib's phase III trials showed rapid, deep skin clearance and strong safety in psoriasis.

Envudeucitinib's Phase 3 success and robust financing position operations through late 2027.

Q3 2025 featured higher expenses, a $110.8M net loss, and strong cash runway into 2027.

Phase 3 psoriasis and phase 2b lupus readouts in 2026 could transform the TYK2 inhibitor landscape.

Key 2024 data readouts for lead TYK2 programs and strong cash position support future growth.

Lead TYK2 inhibitor ESK-001 nears pivotal readouts as pipeline and cash runway support expansion.

Key psoriasis and lupus data for lead TIK2 inhibitor expected in 2025, with strong cash runway.

Lead TYK2 programs in psoriasis and lupus target 2024 readouts, backed by strong data and cash runway.